TopoTarget reports encouraging data from cancer drug trials  

2006.10.27
The Danish biopharmaceutical firm has reported encouraging preliminary results from phase II trials of a compound for the treatment of patients with advanced cancer
Danish biopharmaceutical company TopoTarget has reported encouraging preliminary results from phase II trials of PXD101, a compound for the treatment of patients with advanced cancer. The firm is collaborating with CuraGen Corporation on developing the cancer drug. Peter Buhl Jensen, managing director of TopoTarget comments in a press release:
 
"The results with PXD101 strengthen our expectations of this new type of anticancer agent. PXD101 is well tolerated and appears to be suitable in combinations with anticancer agents normally used today. This opens up opportunities for widespread use of the drug."
 
Timothy Shannon, head of research at CuraGen says the preliminary results from the PXD101 clinical development programme are very encouraging: "We believe these results, combined with the data being generated in the NCI* sponsored trials, will enable us to define the most efficient path toward registration."
 
TopoTarget is headquartered in Denmark, and has subsidiaries in subsidiaries in the UK, Germany and the US. The firm has a broad portfolio of small molecule preclinical drug candidates, and seven drugs in clinical development including novel anti-cancer therapeutics. The news was reported by financial daily newspaper Børsen and on TopoTarget's website.
 
*National Cancer Institute, the US government's principal agency for cancer research – Ed.
 
Link > TopoTarget   
 
Link > CuraGen 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×